Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy) phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): A topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration
Moorthy S.S. Palanki, Hideo Akiyama, Peter Campochiaro, Jianguo Cao, Chun P. Chow, Luis Dellamary, John Doukas, Richard Fine, Colleen Gritzen, John D. Hood, Steven Hu, Shu Kachi, Xinshan Kang, Boris Klebansky, Ahmed Kousba, Dan Lohse, Ching Mak Chi, Michael Martin, Andrew McPherson, Ved P. PathakJoel Renick, Richard Soll, Naoyasu Umeda, Shiyin Yee, Katsutoshi Yokoi, Binqi Zeng, Hong Zhu, Glenn Noronha
Dive into the research topics of 'Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy) phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): A topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration'. Together they form a unique fingerprint.